Serum Dickkopf-1 is increased and correlates with reduced bone mineral density in patients with thalassemia-induced osteoporosis. Reduction post-zoledronic acid administration

Haematologica

Volumn 94, Issue 5, 2009, Pages 725-728

  Voskaridou, Ersi ^a   Christoulas, Dimitrios ^b   Xirakia, Charoula ^a   Varvagiannis, Konstantinos ^a   Boutsikas, Georgios ^b   Bilalis, Antonios ^a   Kastritis, Efstathios ^c   Papatheodorou, Athanasios ^b   Terpos, Evangelos ^b,d  

^a LAIKO GENERAL HOSPITAL   (Greece)

^b 251 GENERAL AIR FORCE HOSPITAL   (Greece)

^c UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^d 252 General Air Force Hospital   (Greece)

Author keywords

Dickkopf 1; Osteoblast; Osteoporosis; Thalassemia; Zoledronic acid

Indexed keywords

DICKKOPF 1 PROTEIN; PLACEBO; WNT PROTEIN; ZOLEDRONIC ACID;

ADULT; ARTICLE; BONE DENSITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; LUMBAR SPINE; MAJOR CLINICAL STUDY; MALE; OSSIFICATION; OSTEOBLAST; OSTEOLYSIS; OSTEOPOROSIS; PATHOGENESIS; PHASE 2 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; THALASSEMIA;

EID: 66049103776     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2008.000893     Document Type: Article

References (20)

1. Voskaridou E, Terpos E. New insights into the pathophysiology and management of osteoporosis in patients with β thalassaemia. Br J Haematol 2004;127:127-139 (Pubitemid 39371805)
2. Voskaridou E, Kyrtsonis MC, Terpos E, Voskaridou E, Kyrtsonis MC, Terpos E, et al. Bone resorption is increased in young adults with thalassaemia major. Br J Haematol 2001;112:36-41.
3. Voskaridou E, Terpos E, Spina G, Skordili M, Palermos J, Rahemtulla A, et al. Pamidronate is an effective treatment for osteoporosis in patients with beta-thalassaemia. Br J Haematol 2003;123:730-737
4. Voskaridou E, Anagnostopoulos A, Konstantopoulos K, Stoupa E, Spyropoulou E, Kiamouris C, et al. Zoledronic acid for the treatment of osteoporosis in patients with β-thalassemia: results from a single-center, randomized, placebo-controlled trial. Haematologica 2006;91:1193-1202
5. Voskaridou E, Christoulas D, Konstantinidou M, Tsiftsakis E, Alexakos P, Terpos E. Continuous improvement of bone mineral density two years post zoledronic acid discontinuation in patients with thalassemia-induced osteoporosis: long-term follow-up of a randomized, placebo-controlled trial. Haematologica 2008;93:1588-1590
6. Lala R, Chiabotto P, Di Stefano M, Isaia GC, Garofalo F, Piga A. Bone density and metabolism in thalassaemia. J Pediatr Endocrinol Metabol 1998;11 (Suppl 3):785-790 (Pubitemid 29065854)
7. Glinka A, Wu W, Delius H, Monaghan AP, Blumenstock C, Niehrs C. Dickkopf-1 is a member of a new family of secreted proteins and functions in head induction. Nature 1998;391:357-362 (Pubitemid 28093502)
8. Zhang Y, Wang Y, Li X, Zhang J, Mao J, Li Z, et al. The LRP5 high-bone mass G171V mutation disrupts LRP5 interaction with Mesd. Mol Cell Biol 2004;24:4677-4684
9. Rawadi G, Vayssière B, Dunn F, Baron R, Roman-Roman S. BMP-2 controls alkaline phosphatase expression and osteoblast mineralization by a Wnt autocrine loop. J Bone Miner Res 2003;18:1842-1853. (Pubitemid 37322562)
10. MacDonald BT, Joiner DM, Oyserman SM, Sharma P, Goldstein SA, He X, et al. Bone mass is inversely proportional to Dkk1 levels in mice. Bone 2007;41:331-339
11. Pinzone JJ, Hall BM, Thudi NK, Vonau M, Qiang YW, Rosol TJ, et al. The role of Dickkopf-1 in bone development, homeostasis and disease. Blood 2009;113:517-525
12. Wang FS, Ko JY, Lin CL, Wu HL, Ke HJ, Tai PJ. Knocking down dickkopf- 1 alleviates estrogen deficiency induction of bone loss. A histomorphological study in ovariectomized rats. Bone 2007;40:485-492
13. Politou M, Heath DJ, Rahemtulla A, Szydlo R, Anagnostopoulos A, Dimopoulos MA, et al. Serum concentrations of Dickkopf-1 protein are increased in patients with multiple myeloma and reduced after autologous stem cell transplantation. Int J Cancer 2006;119:1728-1731
14. Voorzanger-Rousselot N, Goehrig D, Journe F, Doriath V, Body JJ, Clézardin P, et al. Increased Dickkopf-1 expression in breast cancer bone metastases. Br J Cancer 2007;97:964-970
15. Qiang YW, Chen Y, Stephens O, Brown N, Chen B, Epstein J, et al. Myeloma-derived Dickkopf-1 disrupts Wnt-regulated osteoprotegerin and RANKL production by osteoblasts: a potential mechanism underlying osteolytic bone lesions in multiple myeloma. Blood 2008;112: 196-207.
16. Diarra D, Stolina M, Polzer K, Zwerina J, Ominsky MS, Dwyer D, et al. Dickkopf-1 is a master regulator of joint remodeling. Nat Med 2007;13:156-163
17. Voskaridou E, Terpos E. Osteoprotegerin to soluble receptor activator of nuclear factor κ-B ligand ratio is reduced in patients with thalassaemia- related osteoporosis who receive vitamin D3. Eur J Haematol 2005;74:359-361 (Pubitemid 40461158)
18. Morabito N, Russo GT, Gaudio A, Lasco A, Catalano A, Morini E, et al. The "lively" cytokines network in β- thalassemia major-related osteoporosis. Bone 2007;40:1588-1594
19. Gilfillan CP, Strauss BJ, Rodda CP, Bowden DK, Kean AM, Obaid M, et al. A randomized, double-blind, placebo-controlled trial of intravenous zoledronic acid in the treatment of thalassemia-associated osteopenia. Calcif Tissue Int 2006; 79:138-144
20. Perifanis V, Vyzantiadis T, Tziomalos K, Vakalopoulou S, Garipidou V, Athanassiou-Metaxa M, et al. Effect of zoledronic acid on markers of bone turnover and mineral density in osteoporotic patients with β-thalassaemia. Ann Hematol 2007;86:23-30.